WO2000014119A3 - Bifunctional antibodies and their use in targeting anti-tumour agents - Google Patents

Bifunctional antibodies and their use in targeting anti-tumour agents Download PDF

Info

Publication number
WO2000014119A3
WO2000014119A3 PCT/GB1999/002938 GB9902938W WO0014119A3 WO 2000014119 A3 WO2000014119 A3 WO 2000014119A3 GB 9902938 W GB9902938 W GB 9902938W WO 0014119 A3 WO0014119 A3 WO 0014119A3
Authority
WO
WIPO (PCT)
Prior art keywords
bifunctional antibodies
tumour agents
targeting anti
affinity
antibody
Prior art date
Application number
PCT/GB1999/002938
Other languages
French (fr)
Other versions
WO2000014119A2 (en
Inventor
Peter John Harrison
Original Assignee
Ks Biomedix Ltd
Peter John Harrison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002341753A priority Critical patent/CA2341753A1/en
Priority to PL99346861A priority patent/PL346861A1/en
Application filed by Ks Biomedix Ltd, Peter John Harrison filed Critical Ks Biomedix Ltd
Priority to JP2000568876A priority patent/JP2002524470A/en
Priority to KR1020017002437A priority patent/KR20010072988A/en
Priority to EA200100311A priority patent/EA200100311A1/en
Priority to BR9913429-2A priority patent/BR9913429A/en
Priority to AU56412/99A priority patent/AU5641299A/en
Priority to MXPA01002349A priority patent/MXPA01002349A/en
Priority to HU0104091A priority patent/HUP0104091A2/en
Priority to EP99943138A priority patent/EP1107995A2/en
Priority to IL14152499A priority patent/IL141524A0/en
Publication of WO2000014119A2 publication Critical patent/WO2000014119A2/en
Publication of WO2000014119A3 publication Critical patent/WO2000014119A3/en
Priority to BG105293A priority patent/BG105293A/en
Priority to HR20010154A priority patent/HRP20010154A2/en
Priority to NO20011102A priority patent/NO20011102L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Abstract

A bifunctional antibody has affinity for a target site and affinity for an organic molecule covalently linked to a cytotoxic agent or an enzyme capable of converting a prodrug into its cytotoxic form. The antibody may be used in therapy or diagnosis, especially in the treatment of tumours.
PCT/GB1999/002938 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents WO2000014119A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
HU0104091A HUP0104091A2 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents
MXPA01002349A MXPA01002349A (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents.
JP2000568876A JP2002524470A (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeted antitumor agents
PL99346861A PL346861A1 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents
EA200100311A EA200100311A1 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their application for targeted delivery of antitumor agents
BR9913429-2A BR9913429A (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting antitumor agents
EP99943138A EP1107995A2 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents
CA002341753A CA2341753A1 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents
KR1020017002437A KR20010072988A (en) 1998-09-04 1999-09-06 Bifunctional Antibodies and Their Use In Targeting Anti-tumour Agents
AU56412/99A AU5641299A (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents
IL14152499A IL141524A0 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumor agents
BG105293A BG105293A (en) 1998-09-04 2001-02-26 Bifunctional antibodies and their use in targeting anti-tumour agents
HR20010154A HRP20010154A2 (en) 1998-09-04 2001-03-02 Bifunctional antibodies and their use in targeting anti-tumour agents
NO20011102A NO20011102L (en) 1998-09-04 2001-03-02 Bifunctional antibodies and their use in targeting anti-tumor agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9819411.1 1998-09-04
GBGB9819411.1A GB9819411D0 (en) 1998-09-04 1998-09-04 Antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09786013 A-371-Of-International 2001-04-24
US10/445,132 Continuation US20030215387A1 (en) 1998-09-04 2003-05-22 Bifunctional antibodies and their use in targeting anti-tumour agents

Publications (2)

Publication Number Publication Date
WO2000014119A2 WO2000014119A2 (en) 2000-03-16
WO2000014119A3 true WO2000014119A3 (en) 2000-11-30

Family

ID=10838416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002938 WO2000014119A2 (en) 1998-09-04 1999-09-06 Bifunctional antibodies and their use in targeting anti-tumour agents

Country Status (20)

Country Link
EP (1) EP1107995A2 (en)
JP (1) JP2002524470A (en)
KR (1) KR20010072988A (en)
CN (1) CN1315967A (en)
AU (1) AU5641299A (en)
BG (1) BG105293A (en)
BR (1) BR9913429A (en)
CA (1) CA2341753A1 (en)
EA (1) EA200100311A1 (en)
GB (1) GB9819411D0 (en)
HR (1) HRP20010154A2 (en)
HU (1) HUP0104091A2 (en)
ID (1) ID28873A (en)
IL (1) IL141524A0 (en)
MX (1) MXPA01002349A (en)
NO (1) NO20011102L (en)
PL (1) PL346861A1 (en)
TR (2) TR200103405T2 (en)
WO (1) WO2000014119A2 (en)
ZA (1) ZA200101574B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020019232A1 (en) * 2018-07-26 2020-01-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN110811820B (en) * 2019-12-11 2022-07-12 江西华晨医疗设备有限公司 Straight rod type flushing and suction electrocoagulation cutter

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
EP0369566A2 (en) * 1988-11-17 1990-05-23 Hybritech Incorporated Bifunctional chimeric antibodies
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
JPH05184383A (en) * 1990-06-19 1993-07-27 Dainabotsuto Kk Bispecific antibody
WO1998038513A1 (en) * 1997-02-26 1998-09-03 Khaw Ban An Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
EP0369566A2 (en) * 1988-11-17 1990-05-23 Hybritech Incorporated Bifunctional chimeric antibodies
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
JPH05184383A (en) * 1990-06-19 1993-07-27 Dainabotsuto Kk Bispecific antibody
WO1998038513A1 (en) * 1997-02-26 1998-09-03 Khaw Ban An Signal enhancement of bispecific antibody-polymer probe for immunoassay use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF CANCER, vol. 67 367, no. 3, 1993, UK, pages 436 - 440, XP002901232, ISSN: 0007-0920 *
DATABASE DIALOG [online] BRUYNCK A ET AL: "Characterisation of a humanised bispecific monoclonal antibody for cancer therapy", XP002900882, retrieved from EMBASE accession no. 1993077634 *
DATABASE WPI Section Ch Week 199334, Derwent World Patents Index; Class B04, AN 1993-269042, XP002901224 *
HUI ZHU ET AL: "Tumor Pretargeting for Radioimmunodetection and Radioimmunotherapy", J NUCL MED, vol. 39, no. 1, January 1998 (1998-01-01), pages 65 - 76, XP002901225 *

Also Published As

Publication number Publication date
WO2000014119A2 (en) 2000-03-16
EP1107995A2 (en) 2001-06-20
AU5641299A (en) 2000-03-27
EA200100311A1 (en) 2001-08-27
CA2341753A1 (en) 2000-03-16
PL346861A1 (en) 2002-03-11
HRP20010154A2 (en) 2002-02-28
BG105293A (en) 2001-12-29
BR9913429A (en) 2001-09-25
CN1315967A (en) 2001-10-03
ZA200101574B (en) 2002-02-26
NO20011102L (en) 2001-03-05
TR200103405T2 (en) 2002-06-21
KR20010072988A (en) 2001-07-31
IL141524A0 (en) 2002-03-10
HUP0104091A2 (en) 2002-03-28
GB9819411D0 (en) 1998-10-28
NO20011102D0 (en) 2001-03-02
MXPA01002349A (en) 2003-10-15
TR200100651T2 (en) 2001-07-23
JP2002524470A (en) 2002-08-06
ID28873A (en) 2001-07-12

Similar Documents

Publication Publication Date Title
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
ATE383430T1 (en) RECOMBINANT ANTIBODIES AND IMMUNE CONJUGATES TARGETED AT CD22-BEARING CELLS AND TUMORS
CA2318576A1 (en) Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
AU5303700A (en) Immunoconjugates having high binding affinity
WO2000056774A8 (en) Methods of using bioelastomers
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
AU3057297A (en) Targeted combination immunotherapy of cancer
WO2003072754A3 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
ATE296105T1 (en) IMININE-FORMING POLYSACCHARIDES, THEIR PREPARATION AND USE AS ADDITIVES AND IMMUNO-STIMULANT AGENTS
WO2003083041A8 (en) Cripto-specific antibodies
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2000018439A3 (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
RU92016354A (en) COMPOSITION, METHODS OF TREATMENT, METHOD OF PREVENTION OF RECURRENCE, METHOD OF ENHANCING CYTOTOXIC ACTIVITY OF IMMUNOTOXIN, METHOD OF ENHANCING CYTOTOXIC ACTION OF CONJUGATE
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
ZA929575B (en) Bicyclopolyazamacrocyclocarboxyclic acid complexes,their conjugates,processes for their preparation,and use as contrast agents
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
WO2000014119A3 (en) Bifunctional antibodies and their use in targeting anti-tumour agents
ATE187890T1 (en) LIGAND DIRECTED ENZYME PRODRUG THERAPY
BR0008305A (en) Use of an enterobacterium ompa protein, or one of its fragments and pharmaceutical composition
ATE249243T1 (en) BIOTINYLATED ANTIBODIES WITH REDUCED POSITIVE NET LOAD AND TOXIN, DRUG OR CHELATE
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer
WO2002038566A3 (en) Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810368.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999943138

Country of ref document: EP

Ref document number: IN/PCT/2001/00156/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 141524

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-657

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 508574

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1999 105293

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/01574

Country of ref document: ZA

Ref document number: 1020017002437

Country of ref document: KR

Ref document number: 200101574

Country of ref document: ZA

Ref document number: P-151/01

Country of ref document: YU

ENP Entry into the national phase

Ref document number: 2341753

Country of ref document: CA

Ref document number: 2341753

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/00651

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002349

Country of ref document: MX

Ref document number: P20010154A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2000 568876

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 56412/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20010258

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200100311

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09786013

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999943138

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-657

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017002437

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001/03405

Country of ref document: TR

WWW Wipo information: withdrawn in national office

Ref document number: 1999943138

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002437

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-657

Country of ref document: CZ